Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Swiss Cancer Institute
University of Pennsylvania
University of Washington
Barbara Ann Karmanos Cancer Institute
Indiana University
Radboud University Medical Center